| Dr Stephen R Wilber, DO | |
|
624 Hospital Dr, Mountain Home, AR 72653-2955 | |
| (870) 508-1000 | |
| (870) 424-3089 |
| Full Name | Dr Stephen R Wilber |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 24 Years |
| Location | 624 Hospital Dr, Mountain Home, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871544965 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | E-3629 (Arkansas) | Secondary |
| 208M00000X | Hospitalist | E3629 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baxter Regional Medical Center | Mountain home, AR | Hospital |
| Fulton County Hospital | Salem, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| First In Service Hospitalists Pa | 6608825682 | 12 |
News Archive
Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body, today announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration for the treatment of advanced ischemic chronic heart failure.
HeartWare International, Inc. announced today its intention to offer, subject to market and other conditions, $100 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") today. HeartWare also intends to grant the underwriters an option to purchase up to an additional $15 million principal amount of notes to cover over-allotments, if any.
Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.
Industry Standard Research today announced the launch of two new and substantial research reports titled The Future of Clinical Monitoring and Clinical Development Staff Quality and Resourcing Models.
For patients suffering from severe pulmonary diseases including emphysema, lung cancer or fibrosis, transplantation of healthy lung tissue may offer the best chance for survival. The surgical procedure, however, faces two primary challenges: an acute shortage of donor lungs and rejection of transplanted tissue by the recipient's immune system.
› Verified 8 days ago
| Entity Name | Baxter County Regional Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033147921 PECOS PAC ID: 3274420971 Enrollment ID: O20040227000860 |
News Archive
Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body, today announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration for the treatment of advanced ischemic chronic heart failure.
HeartWare International, Inc. announced today its intention to offer, subject to market and other conditions, $100 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") today. HeartWare also intends to grant the underwriters an option to purchase up to an additional $15 million principal amount of notes to cover over-allotments, if any.
Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.
Industry Standard Research today announced the launch of two new and substantial research reports titled The Future of Clinical Monitoring and Clinical Development Staff Quality and Resourcing Models.
For patients suffering from severe pulmonary diseases including emphysema, lung cancer or fibrosis, transplantation of healthy lung tissue may offer the best chance for survival. The surgical procedure, however, faces two primary challenges: an acute shortage of donor lungs and rejection of transplanted tissue by the recipient's immune system.
› Verified 8 days ago
| Entity Name | First In Service Hospitalists Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174609713 PECOS PAC ID: 6608825682 Enrollment ID: O20050117000460 |
News Archive
Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body, today announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration for the treatment of advanced ischemic chronic heart failure.
HeartWare International, Inc. announced today its intention to offer, subject to market and other conditions, $100 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") today. HeartWare also intends to grant the underwriters an option to purchase up to an additional $15 million principal amount of notes to cover over-allotments, if any.
Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.
Industry Standard Research today announced the launch of two new and substantial research reports titled The Future of Clinical Monitoring and Clinical Development Staff Quality and Resourcing Models.
For patients suffering from severe pulmonary diseases including emphysema, lung cancer or fibrosis, transplantation of healthy lung tissue may offer the best chance for survival. The surgical procedure, however, faces two primary challenges: an acute shortage of donor lungs and rejection of transplanted tissue by the recipient's immune system.
› Verified 8 days ago
| Entity Name | Baxter County Regional Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235382631 PECOS PAC ID: 0042389264 Enrollment ID: O20081215000045 |
News Archive
Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body, today announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration for the treatment of advanced ischemic chronic heart failure.
HeartWare International, Inc. announced today its intention to offer, subject to market and other conditions, $100 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") today. HeartWare also intends to grant the underwriters an option to purchase up to an additional $15 million principal amount of notes to cover over-allotments, if any.
Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.
Industry Standard Research today announced the launch of two new and substantial research reports titled The Future of Clinical Monitoring and Clinical Development Staff Quality and Resourcing Models.
For patients suffering from severe pulmonary diseases including emphysema, lung cancer or fibrosis, transplantation of healthy lung tissue may offer the best chance for survival. The surgical procedure, however, faces two primary challenges: an acute shortage of donor lungs and rejection of transplanted tissue by the recipient's immune system.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephen R Wilber, DO 860 Highway 62 E Ste 10, Mountain Home, AR 72653-3200 Ph: (870) 424-3181 | Dr Stephen R Wilber, DO 624 Hospital Dr, Mountain Home, AR 72653-2955 Ph: (870) 508-1000 |
News Archive
Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body, today announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration for the treatment of advanced ischemic chronic heart failure.
HeartWare International, Inc. announced today its intention to offer, subject to market and other conditions, $100 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") today. HeartWare also intends to grant the underwriters an option to purchase up to an additional $15 million principal amount of notes to cover over-allotments, if any.
Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.
Industry Standard Research today announced the launch of two new and substantial research reports titled The Future of Clinical Monitoring and Clinical Development Staff Quality and Resourcing Models.
For patients suffering from severe pulmonary diseases including emphysema, lung cancer or fibrosis, transplantation of healthy lung tissue may offer the best chance for survival. The surgical procedure, however, faces two primary challenges: an acute shortage of donor lungs and rejection of transplanted tissue by the recipient's immune system.
› Verified 8 days ago
Michael Elkins, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 624 Hospital Dr., Mountain Home, AR 72653 Phone: 870-508-1000 Fax: 870-424-3089 | |
Daniel C Goodwin, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 624 Hospital Dr, Mountain Home, AR 72653 Phone: 870-508-1000 Fax: 870-424-3089 | |
Almas Chughtai, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 624 Hospital Dr, Mountain Home, AR 72653 Phone: 870-508-1000 Fax: 870-424-3089 | |
Dr. Arlene Lou Johnson, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 624 Hospital Dr, Mountain Home, AR 72653 Phone: 870-508-1000 | |
Warren Edward Scott Jr., DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 624 Hospital Dr, Mountain Home, AR 72653 Phone: 870-424-3181 Fax: 870-424-3089 | |
Dr. Franklin John Gray Jr., M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 624 Hospital Dr, Suite A, Mountain Home, AR 72653 Phone: 870-508-1000 Fax: 870-424-3089 |